Patients Demographic and clinical characteristics
Forty patients participated in our study, whereby twenty patients had coronary microvascular dysfunction and twenty patients had obstructive coronary artery disease. The mean age was 58.5±12.5 years. Approximately 60% of the patients were women. The mean left ventricular ejection fraction was 56.7±7.9, and the mean coronary flow reserve was 2.04±0.56 respectively. The patient’s demographic and clinical characteristics are summarized in Table 1.
Relationship between left ventricular ejection fraction, low density lipoprotein, Brain natriuretic peptide, Troponin-I and Coronary flow reserve in patients with coronary microvascular disease and obstructive coronary artery disease.
We hypothesized that the factors influencing left ventricular ejection fraction for patients with coronary microvascular disease and obstructive coronary artery disease to be LDL-C, BNP, Troponin-I and CFR. We conducted correlation tests using Spearman’s rho to assess the relationship between LVEF, LDL-C, BNP, Troponin-I and CFR in patients with CMVD and OCAD (Figure 1A, B, C and D). Low density lipoprotein-c (LDL-c) had significant inverse relationship with LVEF (r= -0.323, P= 0.042), LVEF also had significant negative relationship with BNP (r= -0.562, P<.0001), and Troponin-I (r= -0.311, P= 0.04). While a significant positive relationship was observed between LVEF and CFR (r= 0.422, P=0.007).
Relationship between left ventricular ejection fraction, low density lipoprotein and brain natriuretic peptide in patients with obstructive coronary artery disease
Left ventricular ejection fraction had significant negative relationship with LDL-C, and BNP. We observed fewer factors influencing the LVEF when we separated OCAD from CMVD patients, and there was no correlating factor in CMVD subgroup.
Determination of predictors of Left ventricular ejection fraction
i) In patients with coronary microvascular disease and obstructive coronary artery disease
A backward multivariate linear regression model was done for determination of predictors of LVEF in patients with CMVD and OCAD. In this study, the variables Age, symptoms, NYHA classification and BNP qualified to enter the model. After adjusting for confounders, the patients age (coefficient β= 0.19, 95% CI, 39.5-58.6, P= 0.023), Difficulty in breathing (coefficient β= -6.95, 95% CI, (-11.9) -(-2.0), P= 0.007), NYHA Class III (coefficient β= -7.14, 95% CI, (-12.55) -(-1.74), P= 0.011), NYHA Class IV (coefficient β= -17.25, 95% CI, (-26.18) -(-8.32), P<.0001), and BNP (coefficient β= -0.03, 95% CI, (-0.042) -(-0.019), P<.0001) were determined as predictors of LVEF in patients with CMVD and OCAD.
ii) In patients with coronary microvascular disease
After adjusting for confounders, the patients age (coefficient β= 1.31, 95% CI, 1.07-1.55, P<.0001), systolic blood pressure (coefficient β= -0.58, 95% CI, (-0.76)-(-0.41), P<.0001), diastolic blood pressure (coefficient β= -1.71, 95% CI, (-2.14)-(-1.28), P<.0001), HDL (coefficient β= -4.8, 95% CI, (-8.5)- (1.14), P=0.02), HbA1c (coefficient β= 2.69, 95% CI, 1.66- 3.74, P= 0.001), Chest tightness (coefficient β= 33.3, 95% CI, 26.4-40.2, P<.0001), difficulty in breathing (coefficient β= 12.3, 95% CI, 6.93-17.7, P=0.002), NYHA class I (coefficient β= 20.4, 95% CI, 13.3-27.5, P=0.001), alcohol (coefficient β= 20, 95% CI, 15.6-24.6, P<.0001), Hypertension (coefficient β= 57, 95% CI, 47-67, P<.0001), Diabetes mellitus (coefficient β= -64, 95% CI, (-77)- (-51), P<.0001), Troponin I (coefficient β= -1.65, 95% CI, (-1.9)-(-1.3), P<.0001), and BNP (coefficient β= 0.35, 95% CI, 0.24-0.46, P=0.001) were determined as predictors of LVEF in patients with CMVD (Table 2).